Fibronectin binding domains with reduced immunogenicity

Patent metadata

Field	Value
Publication number	US-10464995-B2
Application number	US-201615237484-A
Country	US
Kind code	B2
Filing date	Aug 15, 2016
Priority date	Oct 31, 2011
Publication date	Nov 5, 2019
Grant date	Nov 5, 2019

Abstract

Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.

First claim

What is claimed:

1. A polypeptide comprising a human fibronectin type 3 tenth ( 10 Fn3) domain, which comprises AB, BC, CD, DE, EF, and FG loops and β-strands A, B, C, D, E, F, and G, wherein the amino acid sequences of the BC loop and the CD loop are modified relative to the corresponding loops of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6) and wherein the amino acid sequences of the β-strand C and the β-strand D are modified relative to the corresponding β-strands of the wild-type human 10Fn3 domain (SEQ ID NO: 1 or 6).

2. The polypeptide of claim 1 , wherein at least one north pole loop and at least one south pole loop have the amino acid sequences of the corresponding loops of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

3. The polypeptide of claim 1 , wherein at least a portion of the BC loop has the amino acid sequence of the corresponding loop of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

4. The polypeptide of claim 3 , wherein at least the first 3 residues of the BC loop are the same as the corresponding residues in the BC loop of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

5. The polypeptide of claim 3 , wherein at least the first 4 residues of the BC loop are the same as the corresponding residues in the BC loop of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

6. The polypeptide of claim 3 , wherein at least the first 5 residues of the BC loop are the same as the corresponding residues in the BC loop of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

7. The polypeptide of claim 3 , wherein the polypeptide has reduced immunogenicity relative to an equivalent polypeptide that has additional modifications in the BC loop.

8. The polypeptide of claim 1 , wherein the hydrophobic core residues have not been modified relative to the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

9. The polypeptide of claim 1 , wherein the polypeptide has at least 50% identity to the amino acid sequence of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

10. The polypeptide of claim 1 , wherein the polypeptide has at least 65% identity to the amino acid sequence of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

11. The polypeptide of claim 1 , wherein at least 4 of the 11 amino acids of the CD loop are modified relative to the sequence of the CD loop of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

12. The polypeptide of claim 1 , wherein one or more amino acid residues of the CD loop corresponding to amino acid residues 46 or 47 of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6) are the same as the wild-type amino acids at those positions.

13. The polypeptide of claim 1 , wherein at least the first 6 residues of the BC loop are the same as the corresponding residues in the BC loop of the wild-type human 10 Fn3 domain (SEQ ID NO:1 or 6).

14. The polypeptide of claim 1 , wherein one or more of the AB, DE, and EF loops have the amino acid sequence of the corresponding loop of the wild-type human 10 Fn3 domain (SEQ ID NO: 1 or 6).

15. The polypeptide of claim 1 , wherein the portion of the CD loop corresponding to amino acid residues 40, 41, 42, 43, 44, and/or 45 of the CD loop of the wild-type human 10Fn3 domain (SEQ ID NO: 1 or 6) is modified relative to the same portion of the wild-type CD loop.

16. The polypeptide of claim 1 , wherein each of the modified BC and CD loops contribute to binding to the target.

17. The polypeptide of claim 1 , wherein each of the modified β-strands C and D contribute to binding to the target.

Assignees

• Bristol Myers Squibb Co

Inventors

• Davis Jonathan
• Lipovsek Dasa
• Camphausen Ray

Classifications

• C07K2318/20

  Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics · CPC title

• C07K16/244

  Interleukins [IL] · CPC title

• C07K16/241 Primary

  Tumor Necrosis Factors · CPC title

• C07K16/2833

  against MHC-molecules, e.g. HLA-molecules · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title